Related Experiment Video
Updated: Aug 8, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Circulating catecholamine and potassium concentrations early in acute myocardial infarction: effect of intervention
Abstract:
In a prospective study, 20 patients with a first acute myocardial infarction and no current treatment with diuretics or cardioactive drugs were randomized to treatment with intravenous timolol (10 patients) or placebo (10 patients). Plasma adrenaline, noradrenaline, and serum potassium were estimated at baseline (mean +/- SD 3.6 +/- 0.8 hours after the onset of the infarction) and 4 hours after the start of treatment. The patient selection criteria embraced a low-risk study population. Before treatment, the serum potassium concentrations correlated inversely with plasma adrenaline but not with plasma noradrenaline concentrations. A rise of serum potassium (mean +/- SD mmol/L) from 4.1 +/- 0.3 to 4.4 +/- 0.4 (p less than 0.05) in the placebo group and from 4.0 +/- 0.4 to 4.5 +/- 0.5 (p less than 0.05) in the timolol group was in multivariate analysis associated with infarct size, estimated as cumulative creatine kinase release, in the placebo group, and with the mean individual plasma adrenaline concentrations in the timolol group. By reversing the effect of adrenaline from a decrease to an increase in the serum potassium concentrations, timolol changes the relationships between circulating adrenaline, potassium, and infarct size.
Insights
Timolol treatment in acute myocardial infarction patients altered the relationship between adrenaline and serum potassium. This beta-blocker impacts how adrenaline affects potassium levels and infarct size.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) involves complex physiological responses.
- Catecholamines like adrenaline play a role in cardiac events and electrolyte balance.
Purpose of the Study:
- To investigate the effect of timolol on plasma catecholamines and serum potassium in AMI patients.
- To explore the relationship between these factors and infarct size.
Main Methods:
- Prospective randomized study of 20 low-risk AMI patients.
- Treatment with intravenous timolol or placebo.
- Measurement of plasma adrenaline, noradrenaline, and serum potassium at baseline and 4 hours post-treatment.
Main Results:
- Serum potassium correlated inversely with plasma adrenaline pre-treatment.
- Both placebo and timolol groups showed a significant rise in serum potassium.
- In the placebo group, potassium rise correlated with infarct size; in the timolol group, it correlated with plasma adrenaline levels.
Conclusions:
- Timolol modifies the effect of adrenaline on serum potassium.
- This modulation influences the relationship between circulating adrenaline, potassium levels, and myocardial infarct size.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...